Read More Pharma Industry News H2 Global Group enters growth phase with hydrogen therapy for Alzheimer’s and neurodegenerative diseases H2 Global Group eyes EU and FDA milestones as it advances hydrogen therapy for Alzheimer’s and projects $48M revenues by 2029—read the in-depth analysis. bySoujanya RaviSeptember 30, 2025